Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The scientific aim of this study is to investigate the efficacy and safety of
incobotulinumtoxinA (Xeomin-Merz Pharmaceuticals) in the tremor of Parkinson"s disease. Our
hypothesis is that injection of Xeomin into the muscles of arm, forearm and hand decreases
the tremor amplitude and frequency leading to improvement of the patient"s function.
Phase:
Phase 2
Details
Lead Sponsor:
Yale University
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA